26 results about "Ivermectinum" patented technology

Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the treatment and prevention of pain in humans.

This invention discloses the application and method of a STAT1-targeting inhibitor in the treatment of immune thrombocytopenic purpura (ITP). It employs ivermectin, a STAT1 nuclear translocation inhibitor, and fludarabine, a STAT1 activation inhibitor. By injecting either the activation inhibitor or the nuclear translocation inhibitor, the platelet count in a mouse model of ITP is increased. Fludarabine, a fluorinated nucleotide analog of vidarabine, is non-radioactive and a small-molecule phosphorylation inhibitor. Ivermectin is a small-molecule inhibitor of nuclear translocation mediated by α / β1 introgression protein. Both have high bioavailability and are widely used to treat various hematological diseases with good safety profiles. Their application in treating ITP is safe, effective, and shows high compliance.

The present invention provides an anti-parasitic composition for use in the treatment or prevention of a parasitic infection in a mammal, the anti-parasitic composition comprising a macrolide, in particular a combination of ivermectin, abamectin and doramectin. The invention also provides a method of treating a parasitic infection in a mammal by administering to the mammal an effective amount of an anti-parasitic composition comprising ivermectin, abamectin, and doramectin, and a method of preparing the anti-parasitic composition.

The invention discloses an albendazole-ivermectin compound nanoemulsion and a preparation method of the albendazole-ivermectin compound nanoemulsion. The albendazole-ivermectin nanoemulsion is prepared from albendazole, ivermectin, an oil phase, a surfactant, a cosurfactant and a water phase. The preparation method comprises the following steps: dissolving the medicines in a solvent, extracting to obtain an oil phase, removing the solvent, adding the oil phase into a water phase consisting of the surfactant, the cosurfactant and water under stirring, and spontaneously forming the nano-emulsion through low-energy emulsification. The prepared nanoemulsion is small in particle size and good in stability, the solubility and the drug loading capacity of two insoluble drugs can be remarkably improved, the synergistic parasite expelling effect is achieved, and the cure rate is increased. The preparation process is simple, mild in condition and suitable for industrial production.

The present disclosure relates to methods of diseases and / or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.

The application relates to the technical field of pharmaceutical preparations, and provides an ivermectin external pharmaceutical composition, a preparation method and application.The ivermectin external pharmaceutical composition is mainly composed of ivermectin, a permeation enhancer combination, oil ingredients, an emulsifier, a viscosity regulator and a carrier; the ivermectin content is 0.60%-1.00% w / w; the permeation enhancer combination is a combination of diethylene glycol monoethyl ether, decyl umbelliferrone polyoxyethylene ether 8 and farnesol, and the content is 10%-15% w / w.The application overcomes the defects of the prior art, the composition not only has improved skin permeability and retention, but also is stable and non-greasy, and meanwhile, the production process has scalability, and can ensure uniform dispersion of active ingredients and auxiliary materials.

The application relates to a preparation method of ivermectin, which comprises the following steps: carrying out a hydrogenation reaction on abamectin and hydrogen under the action of catalyst A and catalyst B, and using anhydrous ethanol and toluene as reaction solvents to generate ivermectin; wherein the catalyst A is a copper-cobalt complex catalyst, and the catalyst B is phosphotungstic acid. The catalyst does not contain noble metal, the catalyst cost is reduced, and the separation and purification process is simplified.

This invention relates to the field of veterinary drugs, specifically to an albendazole-ivermectin premix and its preparation method. The premix, by weight percentage (100%), comprises the following raw materials: albendazole 9.5-10.5%, ivermectin microcapsules 0.19-0.21%, sodium chloride 12-24%, and the balance being modified starch. The albendazole-ivermectin premix prepared by this invention can be uniformly mixed through a simple process, exhibiting high homogeneity.

This disclosure relates to methods for treating diseases and / or conditions (including long COVID) associated with Covid-19 infection, the methods comprising administering a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nematvir and ritonavir, monorapvir, a BCG vaccine, or ivermectin.

The present application relates to the technical field of pest control, and specifically discloses a termite control composition and its preparation method. A kind of raw materials used in termite control composition include the following components in parts by weight: 0.9-1 parts of ivermectin emulsifiable concentrate; 1-1.2 parts of attractant; 0.5-0.6 parts of anti-photolysis agent; 4.8-5 parts of water; Its preparation method is: all raw materials are mixed evenly under ultrasonic conditions to obtain a termite control composition. The termite control composition of this application can be used for termite control work, with long-term stable and efficient prevention and control effect, and the degradation half-life under ultraviolet irradiation is not less than 4.21h. In the theoretical experiment of termite control within 2 hours, the average knockdown rate of termites can reach 95.96%, the average mortality rate can reach 82.83%, and the average missing weight ratio of wood blocks within 3 months is 9.42-9.43%.

The present disclosure relates to methods of diseases and / or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.

The application discloses albendazole and ivermectin premix and a preparation method thereof. The premix comprises albendazole 8-15%, ivermectin 0.2-0.4%, double-layer inclusion carrier 20-30% and various auxiliary materials in percentage by mass. The application adopts the double-layer inclusion carrier formed by inner layer hydroxypropyl-beta-cyclodextrin and outer layer hydroxypropyl methylcellulose phthalate and povidone K30 to form an enteric barrier. The preparation method comprises the steps of inner layer inclusion, outer layer dispersion, mixing and granulation. The relative bioavailability of the premix reaches 203%-221%, the pig ascarid drive rate is 98.7%-99.5%, the scabies mite negative conversion rate is 98%-100%, the diarrhea incidence is only 2%-3%, the premix is safe for pregnant sow groups, and no adverse reactions such as abortion, premature birth and loss of appetite occur in all test pigs during the test period. The problems of uneven mixing, low bioavailability and large side effects of traditional preparations are solved, and the premix is suitable for livestock and poultry parasite prevention and treatment.

The present invention relates to a composition comprising ivermectin or pharmaceutically acceptable salt thereof prepared by wet granulation.

The invention discloses genetically engineered streptomyces as well as a construction method and application thereof. According to the present invention, an aveA3 fragment in a Streptomyces avermitilis gene cluster capable of generating an ivermectin B1b compound is replaced with a milA3 fragment in a Streptomyces hygroscopicus gene cluster so as to obtain the gene engineering Streptomyces, such as Streptomyces avermitilis HU501-M, and the gene engineering Streptomyces HU501-M can be used to produce the ivermectin B1b compound, such that the gene engineering Streptomyces HU501-M can be used to produce the ivermectin B1b compound, and the ivermectin B1b compound can be used to produce the ivermectin B1b compound, and the ivermectin B1b compound can be used to produce the ivermectin B1b compound, and can be used to produce the ivermectin B1b compound. The constructed genetically engineered streptomyces can be used for preparing milbemycin D, and the compound has efficient insecticidal, acaricidal and antiparasitic activity, is high in safety to human beings and animals, and is environment-friendly. The main fermentation product of the genetically engineered streptomyces is milbemycins D, and the genetically engineered streptomyces has a good industrial development prospect.

The present invention contemplates the use of inhaled ivermectin for use in various viruses and parasitic infections (treatment and / or prophylaxis) that are present or manifest in the lungs or respiratory tract. Exemplary dosing, formulations, devices, and processing techniques are also disclosed herein.

Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the treatment and prevention of various neurological disorders in humans.

The application belongs to the field of veterinary drugs and discloses an ivermectin enteric granule, which comprises PEG6000, enteric material HPMCP-hp50 and ivermectin, the particle size of the ivermectin enteric granule is 20-50 mesh, the amount of the PEG6000 is equivalent to 54-84% of the total weight of the ivermectin enteric granule, and the amount of the enteric material HPMCP-hp50 is equivalent to 10-15% of the total weight of the ivermectin enteric granule, the granule takes PEG6000 as a skeleton, takes HPMCP-hp50 as an enteric material, and loads ivermectin in the skeleton, through the above structure, the enteric granule can be ensured to be insoluble in gastric juice, to be rapidly released and absorbed in the front section of the intestinal tract, through in-vitro release experiments, it can be found that the release speed can be kept at 67% at least in 1h, through in-vivo pharmacokinetic experiments on the best case piglets, it is found that the Cmax of the piglets orally administered with the ivermectin enteric granule is significantly improved compared with the ivermectin tablet, the average relative bioavailability is increased by about 78%, the absolute bioavailability is increased from 37.4% to 66.5%, and the application further provides a preparation method and application of the ivermectin enteric granule.

The present invention relates to the field of treatment of parasites, in particular to a method of treating subjects suffering from soil transmitted helminths by administering a pharmaceutical composition comprising ivermectin and a benzimidazole carbamate formulated as a fixed-dose combination, a pharmaceutical composition in the form of a fixed-dose combination comprising ivermectin and benzimidazole carbamate, said composition for use in the treatment of subjects suffering from parasites and a method for producing a fixed-dose combination comprising ivermectin and benzimidazole carbamate.

The invention relates to the technical field of reaction kettles, and discloses a reaction kettle for decatalyzing ivermectin, the reaction kettle comprises a kettle body, the top of the kettle body is provided with a feed inlet and a supporting seat, the top of the supporting seat is provided with a motor, and the rear part of an output shaft of the motor is fixedly connected with a rotating shaft; and the two stirring mechanisms are symmetrically distributed on the front side and the rear side of the outer surface of the rotating shaft. After the stirring plates rotate by 90 degrees around the axis of the stirring column, the upper sides and the lower sides of the stirring plates are symmetrically distributed, so that reactants passing through the surfaces of the stirring plates are divided up and down, and the multiple stirring plates are longitudinally distributed at equal intervals, so that the divided reactants collide and contact with one another, and the contact area of the reactants is greatly increased; and the supporting cylinder and the moving frame are used for damaging layering of the shunted reactants, so that the disorder degree of the reactants during stirring is further improved, and the working efficiency of the device can be remarkably improved through the design.

The invention belongs to the field of veterinary drugs, and discloses an ivermectin enteric-coated particle which comprises PEG (polyethylene glycol) 6000, an enteric-coated material HPMCP-hp50 and ivermectin, and the particle size of the ivermectin enteric-coated particle is 20-50 meshes; the dosage of the PEG6000 is equivalent to 54-84% of the total weight of the ivermectin enteric-coated particle, the dosage of the enteric-coated material HPMCP-hp50 is equivalent to 10-15% of the total weight of the ivermectin enteric-coated particle, the particle takes the PEG6000 as a framework, takes the HPMCP-hp50 as the enteric-coated material, and the ivermectin is loaded in the framework, so that the condition that the enteric-coated particle is insoluble in gastric juice can be ensured through the structure; the ivermectin enteric-coated granules can be rapidly released and absorbed in the anterior segment of the intestinal tract, it can be found through an in-vitro release experiment that 67% of the release speed can be kept at the minimum within 1 h, it is found through an in-vivo pharmacokinetic experiment on piglets of the optimal case that the ivermectin enteric-coated granules are drenched by the piglets, compared with ivermectin tablets Cmax, the ivermectin enteric-coated granules are obviously improved, and the relative bioavailability is averagely improved by about 78%; the absolute bioavailability is improved from 37.4% to 66.5%, and meanwhile, the invention further provides a preparation method and application of the ivermectin enteric-coated granules.

The present invention relates to a composition prepared by wet granulation comprising ivermectin or pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipients thereof wherein ivermectin is in external phase of pharmaceutical composition.

The invention relates to an ivermectin action target protein and application thereof, and belongs to the technical field of biomedicine. The invention provides a drug action target protein for ovarian cancer, discloses a mechanism network of the anti-ovarian cancer effect of ivermectin and the intervention effect of ivermectin on an ovarian cancer energy metabolism pathway through experiments, and evaluates the in-vitro / in-vivo anti-ovarian cancer effect of ivermectin and the regulation effect of ivermectin on energy metabolism. The target protein of the ivermectin acting on the ovarian cancer cells is determined through a'click chemistry 'technology, a fluorescent probe technology and a target hooking mode, and then the target protein of the ivermectin acting on the ovarian cancer cells is obtained through further analysis and can be used for prediction, preclinical prevention and individualized medication of the ovarian cancer. The development of clinical medication for ovarian cancer under a medical framework is promoted.

Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the treatment and prevention of various neurological and other disorders in humans.

Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the treatment and prevention of various neurological and other disorders in humans.

The invention belongs to the field of veterinary drug technology, and in particular to a kind of albendazole ivermectin premix and preparation method thereof.The albendazole ivermectin premix includes the following raw materials in parts by weight: 5-10 parts of albendazole, 0.1-0.2 parts of ivermectin, 8-15 parts of modified carboxymethyl cellulose, 5-10 parts of sodium pyruvate, 2-10 parts of sodium lauryl sulfate, 1-5 parts of sodium citrate, 10-20 parts of glucose, and 60-70 parts of beta-cyclodextrin.The modified carboxymethyl cellulose and sodium pyruvate in the premix can act synergistically, further improving the redispersibility and bioavailability of albendazole and ivermectin in the premix, thereby improving drug efficacy.In addition, the premix also has good stability and can be stored for a long time.

Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the prevention, treatment, and control of various inflammatory disorders in humans.